TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04255797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baby massage
Description: The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
Study: NCT04199598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (2.4 μg)
Description: 2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (4.8 μg)
Description: 4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (2.4 μg)
Description: 2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol (2.5 μg)
Description: 2.5 μg (nominal dose) abediterol via DPI, reference
Study: NCT02893735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charisma-Diamond
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek-Z550
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
Study: NCT01222234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol - CKD
Description: Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcitriol - CKD
Description: Calcitriol 0.25 mcg once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol - non-CKD
Description: Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
Study: NCT03342339

Intervention type: OTHER
Group type: OTHER
Intervention: cognitive examination
Description: mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test

Intervention type: OTHER
Group type: OTHER
Intervention: cognitive examination
Description: mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test

Intervention type: OTHER
Group type: OTHER
Intervention: viewing of video
Description: viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
Study: NCT02042131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Crisis Response Plan (E-CRP)
Study: NCT02209636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation measurement
Description: Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Flow-mediated dilation measurement
Description: Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
Study: NCT03342339

Intervention type: OTHER
Group type: OTHER
Intervention: viewing of video
Description: viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
Study: NCT03141645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid loading
Description: Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
Study: NCT05767801

Intervention type: PROCEDURE
Intervention: Evaluation of subclinical inflammation
Description: Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;

Intervention type: PROCEDURE
Intervention: Evaluation of subclinical inflammation
Description: Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
Study: NCT00600860

Intervention type: OTHER
Intervention: No interventions
Description: Only registration of clinical practice
Study: NCT02586402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegol-Sihematide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Study: NCT00711074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: single dose 200mg aqueous solution
Study: NCT04157556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yo-Yo Intermittent Recovery Test Level 1
Description: The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yo-Yo Intermittent Recovery Test Level 1
Description: The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705.
Study: NCT02718300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: 20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: 2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily.
Study: NCT01036061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 Low Dose
Description: GSK618334 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 Low Dose
Description: GSK618334 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 PET subjects
Description: PET subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 PET subjects
Description: PET subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 PET subjects
Description: PET subjects
Study: NCT02209636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic pulse-wave velocity
Description: Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Aortic pulse-wave velocity
Description: Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
Study: NCT02112266

Intervention type: OTHER
Group type: OTHER
Intervention: Mail support
Description: between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without

Intervention type: OTHER
Group type: OTHER
Intervention: no mail support
Description: follow-up without mail support
Study: NCT04419506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
Study: NCT01036061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 Medium Dose
Description: Medium Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 Medium Dose
Description: Medium Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 High Dose
Description: GSK618334 High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 High Dose
Description: GSK618334 High Dose
Study: NCT05635058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Reminisence Therapy
Description: Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
Study: NCT04396054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lag Screws
Description: Method of internal fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double Y-shaped plates
Description: Method of internal fixation
Study: NCT04727112

Intervention type: DRUG
Intervention: Usual care versus primary care
Description: RCT study

Intervention type: DRUG
Intervention: Usual care versus primary care
Description: RCT study
Study: NCT03792919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop current treatment (anti-HBV neucleos(t)ides)
Description: Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keep current treatment (anti-HBV neucleos(t)ides)
Description: Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Study: NCT03901183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based Diet
Description: Patients are guided to change their nutrition to a plant-based diet.
Study: NCT03614624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips
Description: Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
Study: NCT02291380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A for Injection
Description: In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
Study: NCT04995744

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pectoralis Major Pedicle Bone Graft
Description: It is aimed to restore the integrity of the medial cortex with the bone pedicle from the insertion region of the pectoralis major muscle in middle-aged patients with Neer type 4 proximal humerus fractures. Researchers aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method. The investigators aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method.
Study: NCT02360943

Intervention type: OTHER
Intervention: 4 blood samples
Description: PK and / or PD measurements during hospitalization
Study: NCT01226667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly.
Study: NCT02732912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear plugs
Description: The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Mask
Description: The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Description: This night sedation will be given to any patient requesting it, in either group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: This night sedation will be given to any patient requesting it, in either group
Study: NCT04382651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: MAS825 liquid solution for intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study: NCT02924753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
Study: NCT02221427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic progression curve
Description: Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static labour progression curve (F)
Study: NCT02439762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psycho-education (SPC)
Description: This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
Study: NCT00211822

Intervention type: PROCEDURE
Intervention: fMRI
Description: fMRI

Intervention type: PROCEDURE
Intervention: fMRI
Description: fMRI

Intervention type: PROCEDURE
Intervention: fMRI
Description: fMRI